Mattson R H, Williamson P D, Hanahan E
Neurology. 1976 Nov;26(11):1014-7. doi: 10.1212/wnl.26.11.1014.
A group of 27 patients with various types of epilepsy were selected for a 6-month double-blind crossover study to compare the anticonvulsant effect and toxicity of eterobarb and phenobarbital. No statistically significant differences in seizure frequency were found among the 21 patients who completed the 6-month trial, but three others, in whom status epilepticus developed during the crossover from eterobarb to phenobarbital, had to be removed from the trial. The study provided some indication that when eterobarb and phenobarbital were used in high dosage with corresponding high serum barbiturate levels (over 30 mug per milliliter), eterobarb had a superior therapeutic effect. Side effects from both drugs included tiredness, sleepiness, nystagmus, and infrequently ataxia, but serious systemic toxicity did not occur. This study showed that eterobarb is a safe and potent anticonvulsant comparable in efficacy to phenobarbital, and the superior results obtained in some patients with eterobarb therapy indicate that it is an effective alternative anticonvulsant.
选取了27名患有各种类型癫痫的患者进行为期6个月的双盲交叉研究，以比较乙琥胺巴比妥和苯巴比妥的抗惊厥作用及毒性。在完成6个月试验的21名患者中，癫痫发作频率未发现有统计学意义的差异，但另外三名在从乙琥胺巴比妥交叉转换至苯巴比妥期间发生癫痫持续状态的患者不得不退出试验。该研究提供了一些迹象表明，当乙琥胺巴比妥和苯巴比妥以高剂量使用且血清巴比妥酸盐水平相应较高（超过每毫升30微克）时，乙琥胺巴比妥具有更好的治疗效果。两种药物的副作用包括疲倦、嗜睡、眼球震颤，偶尔还有共济失调，但未发生严重的全身毒性。这项研究表明，乙琥胺巴比妥是一种安全有效的抗惊厥药，疗效与苯巴比妥相当，并且在一些接受乙琥胺巴比妥治疗的患者中获得的更好结果表明它是一种有效的替代抗惊厥药。
